Cholesterol lowerling effect of ezetimibe on hypercholesterolemic patients with type2 diabetes.

Cholesterol lowerling effect of ezetimibe on hypercholesterolemic patients with type2 diabetes. - Zetia study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002469

Enrollment

Registered

2009-09-08

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes patients with hypercholesterolemia

Interventions

After hospitalization of type2 diabetes patients, they were treated with diet therapy of hypercholesterolemia (limit of cholesterol intake by less than 300 mg per day). After 1 week, they were treated

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Typr2 diabetes patients with hypercholesterolemia (LDL-c>120mg/dl), which are able to hospitalize.

Exclusion criteria

Exclusion criteria: 1. patients with cerebrovasucular disease (onset within 12 weeks). 2. patients over 500 mg/dl of TG. 3. patients with cardiovascular disease. 4. patients with liver disfunction. 5. patients with renal disfunction. 6. patients who are estimated not to continue this study by serious diseases. 7. patients with familial hypercholesterolemia. 8. secondary hypercholesterolemia. 9. patients with alcholism or medicinal poisoning. 10. medicinal allergy. 11. patients with pregnancy.

Design outcomes

Primary

Measure	Time frame
1. Reduction rate of LDL-C for 1 week after hospitalization. 2. Reduction rate of LDL-C after treatment of ezetimibe.	—

Secondary

Measure	Time frame
1. Reduction rate of TC, HDL-C, TG, RLP-C and sdLDL-C for 1 week after hospitalization. 2. Reduction rate of TC, HDL-C, TG, RLP-C and sdLDL-C after treatment of ezetimibe. 3. Correlation between markers of cholesterol synthesis or absorption and reduction rate of TC, LDL-C, HDL-C, TG, RLP-C and sdLDL-C for 1 week after hospitalization. 4. Correlation between markers of cholesterol synthesis or absorption and reduction rate of TC, LDL-C, HDL-C, TG, RLP-C and sdLDL-C after ezetimibe treatment. 5. Correlation between reduction rate of LDL-C for 1 week after hospitalization and reduction rate of LDL-C after ezetimibe treatment.	—

Measure

Time frame

1. Reduction rate of TC, HDL-C, TG, RLP-C and sdLDL-C for 1 week after hospitalization. 2. Reduction rate of TC, HDL-C, TG, RLP-C and sdLDL-C after treatment of ezetimibe. 3. Correlation between markers of cholesterol synthesis or absorption and reduction rate of TC, LDL-C, HDL-C, TG, RLP-C and sdLDL-C for 1 week after hospitalization. 4. Correlation between markers of cholesterol synthesis or absorption and reduction rate of TC, LDL-C, HDL-C, TG, RLP-C and sdLDL-C after ezetimibe treatment. 5. Correlation between reduction rate of LDL-C for 1 week after hospitalization and reduction rate of LDL-C after ezetimibe treatment.

—

Countries

Japan

Contacts

Public ContactTakeshi Matsumura

Graduate School of Medical Science, Kumamoto University. Department of Metabolic Medicine

takeshim@gpo.kumamoto-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026